Haemonetics Co. (NYSE:HAE) Shares Purchased by Skylands Capital LLC

Skylands Capital LLC grew its stake in shares of Haemonetics Co. (NYSE:HAE) by 16.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,175 shares of the medical instruments supplier’s stock after purchasing an additional 3,875 shares during the quarter. Skylands Capital LLC’s holdings in Haemonetics were worth $2,122,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Global Alpha Capital Management Ltd. acquired a new stake in Haemonetics during the third quarter worth approximately $806,000. Loomis Sayles & Co. L P raised its holdings in Haemonetics by 8.1% during the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock worth $13,171,000 after purchasing an additional 12,310 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in Haemonetics by 174.5% during the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 10,774 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in Haemonetics by 10.9% during the third quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after purchasing an additional 80,783 shares in the last quarter. Finally, Boston Trust Walden Corp raised its holdings in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

NYSE:HAE opened at $62.98 on Monday. The firm’s fifty day moving average price is $72.24 and its 200 day moving average price is $76.37. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a market cap of $3.16 billion, a price-to-earnings ratio of 24.79, a price-to-earnings-growth ratio of 1.11 and a beta of 0.39.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, sell-side analysts expect that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

HAE has been the topic of a number of research analyst reports. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their price objective for the stock from $95.00 to $68.00 in a report on Friday, February 7th. JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock. Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a report on Friday, February 7th. Finally, Needham & Company LLC cut their target price on shares of Haemonetics from $112.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.